Ysios Capital Closes Third Fund, at €216M
- Ysios Capital, Spain-based venture capital firm specialized in the biotechnology sector, closed its third fund, Ysios BioFund 3 (YBF 3), at €216m ($260m)
- The company provides biotech ventures with the resources to develop novel and disruptive therapies for indications with high-unmet medical need
- The total investment size per company will typically be of up to €20m
- Ysios takes lead positions and works closely with entrepreneurial management teams
- Emphasis will be placed on building sustainable companies with business models offering dual paths to liquidity
- More than 60% of the portfolio has already been constructed, with eight investments made in the last 12 months by blue-chip European and US investors
